These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 2644397

  • 1. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB.
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [Abstract] [Full Text] [Related]

  • 2. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF.
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [Abstract] [Full Text] [Related]

  • 3. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
    Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ.
    Blood; 1995 Jul 15; 86(2):451-6. PubMed ID: 7541661
    [Abstract] [Full Text] [Related]

  • 4. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
    Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DM, Scott JG, McCrae J, Murray C, Pantalony D.
    J Clin Oncol; 1993 Apr 15; 11(4):704-11. PubMed ID: 8478664
    [Abstract] [Full Text] [Related]

  • 5. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P.
    J Clin Oncol; 1988 Sep 15; 6(9):1411-6. PubMed ID: 2458439
    [Abstract] [Full Text] [Related]

  • 6. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Spinolo JA, Jagannath S, Velásquez W, Spitzer G, Cabanillas F, Hagemeister F, Horwitz LJ, Dicke KA.
    Leuk Lymphoma; 1993 Jan 15; 9(1-2):71-7. PubMed ID: 8477204
    [Abstract] [Full Text] [Related]

  • 7. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.
    Carella Am, Carlier P, Congiu A, Occhini D, Meloni G, Anselmo AP, Mandelli F, Mazza P, Tura S, Mangoni L.
    Leukemia; 1991 Jan 15; 5 Suppl 1():68-71. PubMed ID: 1890870
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A.
    Bone Marrow Transplant; 1990 Feb 15; 5(2):99-103. PubMed ID: 2310878
    [Abstract] [Full Text] [Related]

  • 9. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
    Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH.
    Blood; 1993 Mar 01; 81(5):1137-45. PubMed ID: 8443375
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF.
    J Clin Oncol; 1994 Sep 01; 12(9):1890-901. PubMed ID: 7916039
    [Abstract] [Full Text] [Related]

  • 11. [Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group].
    Fuchs R, Löffler M, Pfreundschuh M, Dölken G, Gerhartz H, Hagen-Aukamp U, Hiller E, Petsch S, Pflüger KH, Rühl U.
    Med Klin (Munich); 1992 Nov 15; 87(11):555-62. PubMed ID: 1281905
    [Abstract] [Full Text] [Related]

  • 12. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep 15; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE.
    J Clin Oncol; 1990 Apr 15; 8(4):648-56. PubMed ID: 2313334
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S, Dicke KA, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekoop L, Zander AR, Spitzer G.
    Ann Intern Med; 1986 Feb 15; 104(2):163-8. PubMed ID: 3511811
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A, Kàtay I, Rueffer U, Winter S, Tesch H, Engert A, Diehl V, Wickramanayake PD.
    Ann Oncol; 1998 Mar 15; 9(3):289-95. PubMed ID: 9602263
    [Abstract] [Full Text] [Related]

  • 18. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.
    Carella AM, Carlier P, Congiu A, Occhini D, Nati S, Santini G, Pierluigi D, Giordano D, Bacigalupo A, Damasio E.
    Bone Marrow Transplant; 1991 Aug 15; 8(2):99-103. PubMed ID: 1718517
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
    Zinzani PL, Magagnoli M, Frezza G, Barbieri E, Gherlinzoni F, Galuppi A, Bendandi M, Merla E, Albertini P, Babini L, Tura S.
    Leuk Lymphoma; 1999 Feb 15; 32(5-6):553-9. PubMed ID: 10048428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.